FDA Approves GLP-1 pill, Foundayo, for Weight Loss

Health & LifestyleNews
191

Listen to article (english)

Translate to Spanish or other 102 languages!

The Food and Drug Administration (FDA) has approved Eli Lilly’s once-daily oral GLP-1 receptor agonist, orforglipron, for adults with obesity, or overweight with weight-related medical problem. Image for illustration purposes
The Food and Drug Administration (FDA) has approved Eli Lilly’s once-daily oral GLP-1 receptor agonist, orforglipron, for adults with obesity, or overweight with weight-related medical problem. Image for illustration purposes

Mega Doctor News

- Advertisement -

Medical News Today

The Food and Drug Administration (FDA) has approved Eli Lilly’s once-daily oral GLP-1 receptor agonist, orforglipron, for adults with obesity, or overweight with weight-related medical problems.

This approval makes Eli Lilly’s oral GLP-1 receptor agonist, to be marketed as Foundayo, the second GLP-1 drug available in pill form, after Wegovy, which gained approval in December 2025.

- Advertisement -

Follow the link below to Medical News Today to read the full story:

https://www.medicalnewstoday.com/articles/fda-approves-oral-glp-1-pill-foundayo-for-weight-loss

Information source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Texas AG Opens New Medicaid Fraud Investigations Based on Newly Released Federal Data
Next article
Cold, Flu, or Allergies? Key Differences to Watch For

More Articles

New Blood Test Detects Testicular Cancer Missed by Standard Markers

Mayo Clinic researchers have developed a blood-based method that may help detect germ cell tumors, the most common type of testicular cancer, including cases that do not show up on standard blood tests, according to a study published in Nature Communications.

FDA Unveils Roadmap for Real-Time Clinical Evidence

The U.S. Food and Drug Administration announced two major steps as part of an initiative to advance the implementation of real-time clinical trials (RTCT).

AI’s Role in Accelerating Lyme Disease Treatments

Mega Doctor News by Tufts University Newswire - Tufts University researchers are using AI and...

How to Use a Weighted Vest Without Risking Injury

Mega Doctor News CLEVELAND CLINIC - It seems like weighted vests are all...
- Advertisement -